Duvelisib for relapsed non-Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is testing a drug called duvelisib for people with non-Hodgkin lymphoma that has come back or not improved after at least one chemotherapy. The goal is to see how well it works in real life. You would take the drug as a pill, and the study will monitor your progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have one of these lymphoma types: follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Richter syndrome, marginal zone lymphoma, peripheral T-cell lymphoma, or diffuse large B-cell lymphoma.
- You must have already had at least one chemotherapy treatment, and your lymphoma must have come back or not responded to that treatment.
- Your kidneys, liver, and blood counts need to be within a certain range (your doctor can check this).
- You need to be able to take medications to prevent certain infections (like pneumocystis pneumonia and herpes) before starting the study drug.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This trial tests a new drug, DZD8586, against other standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior therapy. The goal is to see if DZD8586 works better or has fewer side effects.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests a new drug, duvelisib, against two standard chemotherapy drugs (gemcitabine or bendamustine) for people with T-cell lymphoma that has come back or not responded to treatment. Duvelisib is a targeted therapy that may work differently than chemotherapy.
This trial tests whether the drug duvelisib can help keep T-cell lymphoma in remission after initial chemotherapy. It is for people who have finished first-line treatment with a CHOP-like regimen, achieved a complete response, and cannot or choose not to have a stem cell transplant.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.